[1]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40-44.[doi:10.3969/j.issn.1671-7414.2019.04.010]
　HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(04):40-44.[doi:10.3969/j.issn.1671-7414.2019.04.010]
点击复制

非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年04期
页码:
40-44
栏目:
论著
出版日期:
2019-08-20

文章信息/Info

Title:
Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer
文章编号:
1671-7414(2019)04-040-05
作者:
黄 刚1; 陈 霏2; 肇玉博1; 张 迪1
(1.陕西中医药大学附属医院检验科, 陕西咸阳 712000; 2.陕西省核工业二一五医院检验科,陕西咸阳 712000)
Author(s):
HUANG Gang1; CHEN Fei2; ZHAO Yu-bo1; ZHANG Di1
(1.Department of Clinical Laboratory, Affiliated Hospital of Traditional Chinese Medicine University of Shaanxi,Shaanxi Xianyang 712000,China; 2.215 Hospital of Nuclear Industry of Shaanxi,Shaanxi Xianyang 712000,China)
关键词:
非小细胞肺癌;  微小RNA-145;  微小RNA-221;  细胞角蛋白片断21-1(CYFRA21-1);  癌胚抗原(CEA)
分类号:
R734.2; R730.43
DOI:
10.3969/j.issn.1671-7414.2019.04.010
文献标志码:
A
摘要:
目的 探讨血浆微小RNA(microRNA,miRNA)-145和miRNA-221表达在非小细胞肺癌(non-small cell lung cancer,NSCLC)术后复发中的诊断价值。方法 选取2016年4月～2018年4月期间在陕西中医药大学附属医院和陕西省核工业二一五医院胸外科行手术切除的55例原发性非小细胞肺癌患者的临床资料进行回顾性分析,依据术后是否复发分为复发组和未复发组.同时选取50例同期体检健康者作为对照组.采用实时聚合酶联反应(real-time polymerase chain reaction,RT-PCR)技术检测NSCLC患者血浆miRNA-145和miRNA-221的表达,采用电化学发光方法检测血清细胞角蛋白片断21-1(CYFRA21-1)和癌胚抗原(CEA)水平,比较分析以上标志物的变化与NSCLC患者术后复发的关系。结果 在对照组、未复发组和复发组中,血浆miRNA-145和miRNA-221的表达分别为0.97±0.27,0.35±0.15,0.17±0.09和0.20±0.11,0.39±0.17,1.06±0.31。未复发组的miRNA-221表达显著高于对照组,而显著低于复发组; 未复发组的miRNA-145表达显著低于对照组,而显著高于复发组; 以上比较的差异均有统计学意义(F=118.73～123.72,均P<0.01)。在对照组、未复发组和复发组中,血清CYFRA21-1(ng/ml)和CEA(ng/ml)水平分别为3.02±1.17,9.05±3.43,47.68±16.72和2.31±2.03,7.37±3.29,29.37±12.49。复发组和未复发组的CYFRA21-1和CEA水平与对照组比较显著增高; 复发组两肿瘤标志物水平与未复发组比较显著增高; 以上比较差异均有统计学意义(F=87.46～96.83,均P<0.01)。在复发组中,血浆miRNA-145和miRNA-221表达具有负相关性(r2=0.772,P<0.01)。 miRNA-145表达分别与CYFRA21-1和CEA水平有负相关性(r2= 0.772～0.794,均P<0.01),而miRNA-221表达分别与CYFRA21-1和CEA水平有正相关性(r2=0.663～0.687,均P<0.01)。血浆miRNA-221和miRNA-145表达在鳞癌中的异常率高于腺癌,在TNMⅢ期中的异常率高于Ⅰ-Ⅱ期(χ2=0.012～0.039,均P<0.05); 两标志物与患者年龄、肿瘤大小和吸烟无明显相关性(χ2=0.301～1.000,均P>0.05)。结论 血浆miRNA-145和miRNA-221的差异表达与NSCLC的病变进展有关,检测血浆miRNA-145和miRNA-221表达可用于监测NSCLC术后的复发。
Abstract:
Objective To investigate the diagnostic value of the expression of microRNA145 and microRNA221 in plasma for postoperative recurrence of non-small cell lung cancer(NSCLC).Methods The clinical data of 55 patients with primary NSCLC who underwent surgical resection at the Department of Thoracic Surgery in Affiliated Hospital of Traditional Chinese Medicine University of Shaanxi and 215 Hospital of Nuclear Industry of Shaanxi from April 2016 to April 2018 were retrospectively analyzed.According towhether the recurrence after surgery,they were divided into recurrent group andnon-recurrent group.At the same time,50 cases of healthy people in the same period were selected as the control group.Real-time polymerase-linked quantitative(RT-PCR)technique was used to detect the expression of miRNA-145 andmiRNA-221 in plasma of patients with NSCLC,serum levels of CYFRA21-1 and CEAwere detected by electrochemiluminescence method.The relationship between the changes of the above markers and the recurrence of NSCLC patients was comparatively analyzed.Results In the control group,non-recurrence group and recurrence group,the expression of plasma microRNA-145 and microRNA-221 were 0.97±0.27,0.35±0.15,0.17±0.09 and 0.20±0.11,0.39±0.17,1.06±0.31,respectively.The expression of miRNA-221 in the non-recurrent group was significantly higher than that in the control group,but significantly lower than that in the recurrent group.The expression of miRNA-145 was significantly lower than that in the control group,and significantly higher thanthat in the recurrent group.The above differences were statistically significant(F=118.73～123.72,all P<0.01).The expression of serum CYFRA21-1(ng/ml)and CEA(ng/ml)in the control group,non-recurrence group and recurrence group were 3.02±1.17,9.05±3.43,47.68±16.72 and 2.31±2.03,7.37±3.29,29.37±12.49,respectively.Compared with the control group,the levels of CYFRA21-1 and CEA in the recurrent group and non-recurrence group weresignificantly increased.Compared with the non-recurrence group,the levels ofthe two tumor indicators in the recurrent group were significantly increased.The above differences were statistically significant(F=87.46～96.83,all P<0.01).A negative correlation was showed between plasma expression of miRNA-145 and miRNA-221(r2=0.772,P<0.01).miRNA-145 expression was negatively correlated with the levels of CYFRA21-1 and CEA(r2=0.772～0.794,all P<0.01),while miRNA-221 was positively correlated with the levels CYFRA21-1 and CEA(r2=0.663～0.687,all P<0.01).The abnormal rateof the plasma expressions of microRNA-221 and microRNA-145 in squamous cell carcinoma was higher than that in adenocarcinoma,and in TNM stage III was higherthan that in stage I～II(χ2=0.012～0.039,all P<0.05).There was no significant correlation between the two markers and patient's age,tumor sizeand smoking(χ2=0.301～1.000,all P>0.05).ConclusionThe differential expressions of miRNA-145 and miRNA-221 in plasmawere related to the progression of NSCLC.Detection of plasma expressions of miRNA-145 and miRNA-221 can be used to monitor recurrence after NSCLC.

参考文献/References:

[1] 鲁丹,万彦彬,赖馨,等.血清CEA,NSE,CYFRA21-1水平与非小细胞肺癌病理分期的相关性[J].中国实验诊断学,2016,20(6):912-914. LU Dan,WAN Yanbin,LAI Xin,et al.Level of serum CEA,NSE,CYFRA21-1 correlation with pathological staging of non-small cell lung cancer[J].Chinese Journal of Laboratory Diagnosis,2016,20(6):912-914. [2] HA Minju,KIM V N.Regulation of microRNA biogenesis[J].Nat Rev Mol Cell Biol,2014,15(8):509-524. [3] 王传新.肺癌早期诊断的新肿瘤标志研究[J/OL].中华临床实验室管理(电子杂志),2017,5(4):212-216. WANG Chuanxin.Research of new tumor biomarkers for early diagnosis of lung cancer[J].Chinese Journal of Clinical Laboratory Management(Electronic Edition),2017,5(4):212-216. [4] SUI Ankui,ZHANG Xifeng,ZHU Qing.Diagnostic value of serum miR197 and miR145 in non-small cell lung cancer[J].Oncol Lett,2019,17(3):3247-3252. [5] 强勇,杨楠,张雷,等.非小细胞肺癌患者血清中miRNA-145的表达和意义[J].医学研究生学报,2016,29(1):62-65. QIANG Yong,YANG Nan,ZHANG Lei,et al.Expression serum microRNA145 in patients with non-small cell lung cancer and its clinical significance[J].Journal of Medical Postgreduates,2016,29(1):62-65. [6] YE Zhiqiang,SHEN Ning,WENG Yimin,et al.Low miR-145 silenced by DNA methylation promotes NSCLC cell proliferation,migration and invasion by targeting mucin[J].Cancer Biol Ther,2015,16(7):1071-1079. [7] 张潍,张伟,王辉,等.miRNA-141,miRNA-145在非小细胞肺癌中的表达及与临床病理的关系[J].西安交通大学学报(医学版),2015,36(3):368-372. ZHANG Wei,ZHANG Wei,WANG Hui,et al.Expression of miRNA141 and miRNA145 in non-small cell lung cancer,and their relation with clinicalpathology[J].Journal of Xi'an Jiaotong University(Medical Sciences),2015,36(3):368-372. [8] 吴展陵,钟敏华.MicroRNA-221对非小细胞肺癌NCI-H1299细胞生长的影响及其机制研究[J].解放军医药杂志,2016,28(6):36-40. WU Zhanling,ZHONG Minhua.Effect of microRNA-221 on NCI-H1299 cells growth in non-small-cell lungcancer[J].Medical &Pharmaceutical Journalof Chinese People's Liberation Army,2016,28(6):36-40. [9] 王峰,李梅,朱建伟,等.miRNA-221在行完全切除术非小细胞肺癌中的表达及患者生存分析[J].东南大学学报(医学版),2016,35(3):332-336. WANG Feng,LI Mei,ZHU Jianwei,et al.Expression of miRNA221 and its correlation with survival in non-small cell lung cancer[J].Journal of Southeast University(Medical Sciences Edition),2016,35(3):332-336. [10] 李犹龙,范江.5种miRNA表达对NSCLC患者临床预后的影响[J].热带医学杂志,2016,16(12):1498-1500,1507. LI Youlong,FAN Jiang.Peripheral blood miRNAs and the prognosis of NSCLC[J].Journal of Tropical Medicine,2016,16(12):1498-1500,1507. [11] 田应选,余敏,孙莉,等.五种血清肿瘤标志物检测对非小细胞肺癌术后复发诊断研究[J].现代检验医学杂志,2014,29(3):37-39. TIAN Yingxuan,YU Min,SUN Li,et al.Application of tumor markers for early diagnosis in the postoperative recidivation of NSCLC[J].Journal of ModernLaboratory Medicine,2014,29(3):37-39.

相似文献/References:

[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
　ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(04):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
　XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(04):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
　WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR) Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(04):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3，CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
　YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3， CYFRA21-1，TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(04):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
　QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(04):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
　LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(04):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
　LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(04):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]郭 华a,齐宗利a,张海祥b,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
　GUO Huaa,QI Zong-lia,ZHANG Hai-xiangb,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(04):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
[9]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体（EGFR）基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
　JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor （EGFR）Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(04):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
[10]彭　琦a,程少鹏b,陈辅萍a.非小细胞肺癌组织中NSE 的基因表达及与患者临床特征的相关性研究[J].现代检验医学杂志,2020,35(03):36.[doi:10.3969/j.issn.1671-7414.2020.03.008]
　PENG Qia,CHENG Shao-pengb,CHEN Fu-pinga.Correlation between NSE Gene Expression and Serum NSE Level in Tumor Tissues and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2020,35(04):36.[doi:10.3969/j.issn.1671-7414.2020.03.008]

备注/Memo

备注/Memo:
作者简介:黄 刚(1979-),男,大学本科,主管检验师,研究方向:疾病的基因诊断,E-mail:3436309161@qq.com。 通讯作者:陈 霏(1985-),女,大学本科,主管检验师,研究方向:疾病的基因诊断,E-mail:3499337430@qq.com。收稿日期:2019-05-07 修回日期:2019-05-09
更新日期/Last Update: 2019-07-30